Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of General Internal Medicine
Published in: Journal of General Internal Medicine 1/2008

Open Access 01-01-2008 | Perspectives

Proteomics as a Method for Early Detection of Cancer: A Review of Proteomics, Exhaled Breath Condensate, and Lung Cancer Screening

Authors: Dean H. Conrad, Jesse Goyette, Paul S. Thomas

Published in: Journal of General Internal Medicine | Special Issue 1/2008

Login to get access

Abstract

The study of expressed proteins in neoplasia is undergoing a revolution with the advent of proteomic analysis. Unlike genomic studies where individual changes may have no functional significance, protein expression is closely aligned with cellular activity. This perspective will review proteomics as a method of detecting markers of neoplasia with a particular emphasis on lung cancer and the potential to sample the lung by exhaled breath condensate (EBC). EBC collection is a simple, new, and noninvasive technique, which allows sampling of lower respiratory tract fluid. EBC enables the study of a wide variety of biological markers from low molecular weight mediators to macromolecules, such as proteins, in a range of pulmonary diseases. EBC may be applied to the detection of lung cancer where it could be a tool in early diagnosis. This perspective will explore the potential of applying proteomics to the EBC from lung cancer patients as an example of detecting potential biomarkers of disease and progression.
Literature
1.
Mathers C, Boschi-Pinto C. Global burden of cancer in the year 2000: version 1 estimates. Geneva: World Health Organization, Global Program on Evidence for Health Policy (GPE); 2003.
2.
Kumar V, Cotran RS, Robbins SL. Robbins Basic Pathology, 7th Ed. Philadelphia: Saunders; 2003.
3.
4.
Granville CA, Dennis PA. An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol. 2005;32(3):169–76.PubMedCrossRef
5.
6.
Reed MF, Molloy M, Dalton EL, Howington JA. Survival after resection for lung cancer is the outcome that matters. Am J Surg. 2004;188:598–602.PubMedCrossRef
7.
8.
Gazdar AF, Minna JD. Molecular detection of early lung cancer. J Natl Cancer Inst. 1999;91(4):299–301.PubMedCrossRef
9.
Coley CM, Barry MJ, Fleming C, Fahs MC, Mulley AG. Early detection of prostate cancer. Part II: estimating the risks, benefits, and costs. American College of Physicians. Ann Intern Med. 1997;126(6):468–79.
10.
Phillips M, Gleeson K, Hughes JM, et al. Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet. 1999;353(9168):1930–3.PubMedCrossRef
11.
Mutlu GM, Garey KW, Robbins RA, Danziger LH, Rubinstein I. Collection and analysis of exhaled breath condensate in humans. Am J Respir Crit Care Med. 2001;164(5):731–7.PubMed
12.
13.
Alessandro R, Fontana S, Kohn E, De Leo G. Proteomic strategies and their application in cancer research. Tumori. 2005;91(6):447–55.PubMed
14.
Banks R, Selby P. Clinical proteomics—insights into pathologies and benefits for patients. Lancet. 2003;362(9382):415–6.PubMedCrossRef
15.
Healy DA, Hayes CJ, Leonard P, et al. Biosensor developments: application to prostate-specific antigen detection. Trends Biotechnol. 2007;25(3):125–31.PubMedCrossRef
16.
Meyer MH, Hartmann M, Krause HJ, et al. CRP determination based on a novel magnetic biosensor. Biosens Bioelectron. 2007;22(6):973–9.PubMedCrossRef
17.
Wu J, Tang J, Dai Z, et al. A disposable electrochemical immunosensor for flow injection immunoassay of carcinoembryonic antigen. Biosens Bioelectron. 2006;22(1):102–8.PubMedCrossRef
18.
Kikuchi T, Carbone DP. Proteomics analysis in lung cancer: challenges and opportunities. Respirology. 2007;12:22–8.PubMedCrossRef
19.
Au NHC, Cheang M, Huntsman DG, et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol. 2004;204(1):101–9.PubMedCrossRef
20.
Ullmann R, Morbini P, Halbwedl I, et al. Protein expression profiles in adenocarcinomas and squamous cell carcinomas of the lung generated using tissue microarrays. J Pathol. 2004;203(3):798–807.PubMedCrossRef
21.
22.
Okano T, Kondo T, Kakisaka T, et al. Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics. 2006;6:3938–48.PubMedCrossRef
23.
Chuthapisith S, Layfield R, Kerr ID, Eremin O. Principles of proteomics and its applications in cancer. Surgeon. 2007;5(1):14–22.PubMedCrossRef
24.
Kuramitsu Y, Nakamura K, Kuramitsu Y, Nakamura K. Proteomic analysis of cancer tissues: shedding light on carcinogenesis and possible biomarkers. Proteomics. 2006;6(20):5650–61.PubMedCrossRef
25.
Okusaka T, Yamada T, Maekawa M, Okusaka T, Yamada T, Maekawa M. Serum tumor markers for pancreatic cancer: the dawn of new era? JOP. 2006;7(4):332–6.PubMed
26.
Petricoin EF III, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002;359:572–7.PubMedCrossRef
27.
Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst. 2004;96(5):353–6.PubMedCrossRef
28.
Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics. 2004;3(4):367–78.PubMedCrossRef
29.
Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer. 2004;4(4):309–14.PubMedCrossRef
30.
31.
Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. Computed tomography screening and lung cancer outcomes. JAMA. 2007;297(9):953–61.PubMedCrossRef
32.
International Early Lung Cancer Action Program Investigators; Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006;355(17):1763–71.PubMedCrossRef
33.
Fontana RS, Sanderson DR, Taylor WF, et al. Early lung cancer detection—results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study. Am Rev Respir Dis. 1984;130(4):561–5.PubMed
34.
Read C, Janes S, George J, Spiro S. Early lung cancer: screening and detection. Prim Care Respir J. 2006;15:332–6.PubMedCrossRef
35.
Swensen SJ, Jett JR, Hartman TE, et al. Lung cancer screening with CT: Mayo Clinic experience. Radiology. 2003;226(3):756–61.PubMedCrossRef
36.
Horvath I, Hunt J, Barnes PJ. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J. 2005;26(3):523–48.PubMedCrossRef
37.
Rosias PPR, Dompeling E, Hendriks HJE, Heijnens JWCM, Donckerwolcke RAMG, Jobsis Q. Exhaled breath condensate in children: pearls and pitfalls. Pediatr Allergy Immunol. 2004;15(1):4–19.PubMedCrossRef
38.
Montuschi P, Barnes PJ. Analysis of exhaled breath condensate for monitoring airway inflammation. Trends Pharmacol Sci. 2002;23(5):232–7.PubMedCrossRef
39.
Liu J, Thomas PS. Exhaled breath condensate as a method of sampling airway nitric oxide and other markers of inflammation. Med Sci Monit. 2005;11(5):MT53–62.PubMed
40.
Dwyer TM. Sampling airway surface liquid: non-volatiles in the exhaled breath condensate. Lung. 2004;182(4):241–50.PubMedCrossRef
41.
Garey KW, Neuhauser MM, Robbins RA, Danziger LH, Rubinstein I. Markers of inflammation in exhaled breath condensate of young healthy smokers. Chest. 2004;125(1):22–6.PubMedCrossRef
42.
Carpagnano GE, Foschino-Barbaro MP, Resta O, Gramiccioni E, Carpagnano F. Endothelin-1 is increased in the breath condensate of patients with non-small-cell lung cancer. Oncology. 2004;66(3):180–4.PubMedCrossRef
43.
Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary disease. Am J Respir Crit Care Med. 2001;163:1693–722.PubMed
44.
Carpagnano GE, Foschino-Barbaro MP, Mule G, et al. 3p microsatellite alterations in exhaled breath condensate from patients with non-small cell lung cancer. Am J Respir Crit Care Med. 2005;172(6):738–44.PubMedCrossRef
45.
McCafferty JB, Bradshaw TA, Tate S, Greening AP, Innes JA. Effects of breathing pattern and inspired air conditions on breath condensate volume, pH, nitrite, and protein concentrations. Thorax. 2004;59(8):694–8.PubMedCrossRef
46.
Liu J, Conrad DH, Chow S, Tran VH, Yates DH, Thomas PS. Collection devices influence the constituents of exhaled breath condensate. Eur Respir J 2007;in press.
47.
Rosias PPR, Robroeks CM, Niemark HJ, et al. Exhaled breath condensate in children: pearls and pitfalls. Pediatr Allergy Immunol. 2004;15(1):4–19.PubMedCrossRef
48.
Griese M, Noss J, von Bredow C. Protein pattern of exhaled breath condensate and saliva. Proteomics. 2002;2(6):690–6.PubMedCrossRef
49.
Liu J, Thomas PS. Relationship between exhaled breath condensate volume and measurements of lung volumes. Respiration. 2007;74:142–5.PubMedCrossRef
50.
Carpagnano GE, Barbaro MPF, Resta O, et al. Exhaled markers in the monitoring of airways inflammation and its response to steroid treatment in mild persistent asthma. Eur J Pharmacol. 2005;519(1–2):175–81.PubMedCrossRef
51.
Canton M, Neverova I, Menabò R, Van Eyk J, Di Lisa F. Evidence of myofibrillar protein oxidation induced by postischemic reperfusion in isolated rat hearts. Am J Physiol Heart Circ Physiol. 2004;286(3):H870–7.PubMedCrossRef
52.
53.
Carpagnano GE, Resta O, Foschino-Barbaro MP, Gramiccioni E, Carpagnano F. Interleukin-6 is increased in breath condensate of patients with non-small cell lung cancer. Int J Biol Markers. 2002;17(2):141–5.PubMed
54.
Xiao X, Liu D, Tang Y, Guo F, Xia L, Liu J, He D. Development of proteomic patterns for detecting lung cancer. Dis Markers. 2003;19(1):33–9.PubMed
55.
Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer. 2003;40(3):267–79.PubMed
Metadata
Title
Proteomics as a Method for Early Detection of Cancer: A Review of Proteomics, Exhaled Breath Condensate, and Lung Cancer Screening
Authors
Dean H. Conrad
Jesse Goyette
Paul S. Thomas
Publication date
01-01-2008
Publisher
Springer-Verlag
Published in
Journal of General Internal Medicine / Issue Special Issue 1/2008
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-007-0411-1

Other articles of this Special Issue 1/2008

Journal of General Internal Medicine 1/2008 Go to the issue

Perspectives

Telecardiology and Remote Monitoring of Implanted Electrical Devices: The Potential for Fresh Clinical Care Perspectives

Perspectives

Who is Responsible for Evaluating the Safety and Effectiveness of Medical Devices? The Role of Independent Technology Assessment

Original Article

“That’s Like an Act of Suicide” Patients’ Attitudes Toward Deactivation of Implantable Defibrillators

Editorial

Computerized Clinical Decision Support: Will it Transform Healthcare?

Innovations in Education

Simulation Technology for Skills Training and Competency Assessment in Medical Education

Perspectives

Within You / Without You: Biotechnology, Ontology, and Ethics
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits